LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

Search

Akebia Therapeutics Inc

Closed

SectorHealthcare

3.57 0.85

Overview

Share price change

24h

Current

Min

3.53

Max

3.67

Key metrics

By Trading Economics

Income

29M

6.1M

Sales

11M

57M

EPS

0.025

Profit margin

10.66

Employees

181

EBITDA

20M

14M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+89.61% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

395M

1B

Previous open

2.72

Previous close

3.57

News Sentiment

By Acuity

20%

80%

33 / 381 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Akebia Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Jun 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

KKR to Acquire Australian Power Provider Zenith Energy

16 Jun 2025, 21:55 UTC

Major Market Movers

Geospace Technologies Shares Up on Petrobras Pact

16 Jun 2025, 17:04 UTC

Major Market Movers

Roku Shares Climb on Advertising Deal with Amazon

16 Jun 2025, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 Jun 2025, 23:51 UTC

Market Talk

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

16 Jun 2025, 23:41 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

16 Jun 2025, 23:10 UTC

Market Talk
Acquisitions, Mergers, Takeovers

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

16 Jun 2025, 23:02 UTC

Market Talk

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

16 Jun 2025, 22:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

16 Jun 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

16 Jun 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

16 Jun 2025, 21:56 UTC

Earnings

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

16 Jun 2025, 21:10 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

16 Jun 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 Jun 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

16 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 Jun 2025, 20:49 UTC

Market Talk

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

16 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

16 Jun 2025, 20:13 UTC

Market Talk

Natural Gas Gains on Warmer Outlook -- Market Talk

16 Jun 2025, 19:58 UTC

Acquisitions, Mergers, Takeovers

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

16 Jun 2025, 19:13 UTC

Market Talk

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

16 Jun 2025, 19:09 UTC

Market Talk

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

16 Jun 2025, 18:43 UTC

Market Talk

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

16 Jun 2025, 18:36 UTC

Market Talk

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

16 Jun 2025, 18:29 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Jun 2025, 18:29 UTC

Market Talk

Shopify Appears More Resilient Than Feared -- Market Talk

16 Jun 2025, 18:22 UTC

Market Talk

Citi Forecasts Downturn in Gold Futures -- Market Talk

16 Jun 2025, 16:42 UTC

Market Talk

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

16 Jun 2025, 16:37 UTC

Market Talk

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

16 Jun 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Akebia Therapeutics Inc Forecast

Price Target

By TipRanks

89.61% upside

12 Months Forecast

Average 6.75 USD  89.61%

High 8 USD

Low 6 USD

Based on 4 Wall Street analysts offering 12 month price targets forAkebia Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

2.345 / N/ASupport & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

33 / 381 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.